The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma

Oncology Reports

Volumn 17, Issue 6, 2007, Pages 1399-1404

  Haas, Helga Susanne ^a   Pfragner, Roswitha ^a   Siegl, Veronika ^a   Ingolic, Elisabeth ^b   Heintz, Elfgard ^a   Schraml, Elisabeth ^a   Schauenstein, Konrad ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Cell proliferation; Human melanoma; Metabotropic glutamate receptors; Non competitive metabotropic glutamate receptor antagonist; Tumor growth

Indexed keywords

7 (HYDROXYIMINO)CYCLOPROPAN(B)CHROMEN 1A CARBXOYLIC ACID ETHYL ESTER; 7-(HYDROXYIMINO)CYCLOPROPAN(B)CHROMEN-1A-CARBXOYLIC ACID ETHYL ESTER; AMINO ACID RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; DOCETAXEL; GLUTAMIC ACID; METABOTROPIC RECEPTOR; TAXOID; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; HUMAN; MELANOMA; METABOLISM; SKIN TUMOR; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHROMONES; DRUG RESISTANCE, NEOPLASM; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; MELANOMA; RECEPTORS, METABOTROPIC GLUTAMATE; SKIN NEOPLASMS; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 34548029995     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.6.1399     Document Type: Article

References (28)

1. Ozawa S, Kamiya H and Tsuzuki K: Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 54: 581-618, 1998. (Pubitemid 28123327)
2. Bennett MR and Balcar VJ: Forty years of amino acid transmission in the brain. Neurochem Int 35: 269-280, 1999. (Pubitemid 29341477)
3. Pin JP and Acher F: The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord 1: 297-317, 2002.
4. Parsons CG, Danysz W and Quack G: Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11: 523-569, 1998. (Pubitemid 29086561)
5. Niswender CM, Jones CK and Conn PJ: New therapeutic frontiers for metabotropic glutamate receptors. Curr Top Med Chem 5: 847-857, 2005. (Pubitemid 41269559)
6. Gill S and Pulido O (eds). Glutamate Receptors in Peripheral Tissue. Kluwer Academic/Plenum Publishers, New York, 2005.
7. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K, Tenkova TI, Stefovska V, Turski L and Olney JW: Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283: 70-74, 1999. (Pubitemid 29044848)
8. Luján R, Shigemoto R and López-Bendito G: Glutamate and GABA receptor signalling in the developing brain. Neuroscience 130: 576-580, 2005.
9. Rzeski W, Turski L and Ikonomidou C: Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98: 6372-6377, 2001. (Pubitemid 32488244)
10. Haas HS, Pfragner R, Siegl V, Ingolic E, Heintz E and Schauenstein K: Glutamate receptor-mediated effects on growth and morphology of human histiocytic lymphoma cells. Int J Oncol 27: 867-874, 2005.
11. Choi S-W, Park S-Y, Hong S-P, Pai H, Choi J-Y and Kim S-G: The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinoma. J Oral Pathol Med 33: 533-537, 2004. (Pubitemid 39318463)
12. Li S, Huang S and Peng S-B: Overexpression of G protein-coupled receptors in cancer cells: Involvement in tumor progression. Int J Oncol 27: 1329-1339, 2005.
13. Chang HJ, Yoo BC, Lim S-B, Jeong S-Y, Kim WH and Park J-G: Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res 11: 3288-3295, 2005. (Pubitemid 40627877)
14. Kalariti N, Lembessis P and Koutsilieris M: Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res 24: 3923-2929, 2004.
15. Pacheco R, Ciruela F, Casadó V, Mallol J, Gallart T, Lluis C and Franco R: Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J Biol Chem 279: 33352-33358, 2004. (Pubitemid 39062983)
16. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, Zhu H, Robbins C, Makalowska I, Shin SS, Marin Y, Roberts KG, Yudt LM, Chen A, Cheng J, Incao A, Pinkett HW, Graham CL, Dunn K, Crespo-Carbone SM, Mackason KR, Ryan KB, Sinsimer D, Goydos J, Reuhl KR, Eckhaus M, Meltzer PS, Pavan WJ, Trent JM and Chen S: Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 34: 108-112, 2003. (Pubitemid 36548800)
17. Marín YE and Chen S: Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development. J Mol Med 82: 735-749, 2004. (Pubitemid 40022267)
18. Marín YE, Namkoong J, Cohen-Solal K, Shin S-S, Martino JJ, Oka M and Chen S: Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal 18: 1279-1286, 2006. (Pubitemid 43674044)
19. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prezeau L, Pin J-P, Thomsen C and Kuhn R: CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55: 453-461, 1999. (Pubitemid 29128101)
20. Sun W and Schuchter LM: Metastatic melanoma. Curr Treat Options Oncol 2: 193-202, 2001.
21. Bafaloukos D, Aravantinos G, Fountzilas G, Stathopoulos G, Gogas H, Samonis G, Briasoulis E, Mylonakis N, Skarlos DV and Kosmidis P: Docetaxel in combination with dacarbazine in patients with advanced melanoma. Oncology 63: 333-337, 2002. (Pubitemid 36151525)
22. Atallah E and Flaherty L: Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6: 185-193, 2005. (Pubitemid 40945448)
23. Chawla-Sarkar M, Leaman DW, Jacobs BS and Borden EC: IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 169: 847-855, 2002. (Pubitemid 34753441)
24. Xiang JH and Kimura AK: In vitro modulation of the metastatic phenotype. I. Analysis of differentiation forms of the B16 melanoma expressing Met-72 determinants and metastatic activity. Clin Exp Metastasis 4: 293-309, 1986.
25. Ritzén A, Mathiesen JM and Thomsen C: Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol 97: 202-213, 2005. (Pubitemid 41435091)
26. Kew JNC: Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol Ther 104: 233-244, 2004.
27. Kohara A, Toya T, Tamura S, Watabiki T, Nagakura Y, Shitaka Y, Hayashibe S, Kawabata S and Okada M: Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl- N,3-dimethylthiazolo[3,2-a] benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1. J Pharmacol Exp Ther 315: 163-169, 2005. (Pubitemid 41380509)
28. Namkoong J, Martino JJ and Chen S: From existing therapies to novel targets: a current view on melanoma. Front Biosci 11: 2081-2092, 2006. (Pubitemid 43822542)